Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Janet Dancey

Showing results (31-40 of 71) with videos related to

Pageof 8
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 21, 2007
Randomized trial of high-dose chemotherapy with autologous peripheral-blood stem-cell support compared with standard-dose chemotherapy in women with metastatic breast cancer: NCIC MA.16Michael Crump, Stefan Gluck, Dongsheng Tu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 15, 2010
Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago phase II consortiumSonali M Smith, Koen van Besien, Theodore Karrison, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 19, 2007
Phase I targeted combination trial of sorafenib and erlotinib in patients with advanced solid tumorsIgnacio Duran, Sebastien J Hotté, Holger Hirte, et al.
European Journal of Human Genetics : EJHG|July 18, 2013
Testing personalized medicine: patient and physician expectations of next-generation genomic sequencing in late-stage cancer careFiona A Miller, Robin Z Hayeems, Jessica P Bytautas, et al.
Investigational New Drugs|August 5, 2004
Phase I/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugsSusan M Chang, John Kuhn, Patrick Wen, et al.
International Journal of Radiation Oncology, Biology, Physics|November 3, 2009
Molecular and clinical responses in a pilot study of gefitinib with paclitaxel and radiation in locally advanced head-and-neck cancerCarter Van Waes, Clint T Allen, Deborah Citrin, et al.
Cancer Gene Therapy|September 23, 2003
A phase I trial of adenovector-mediated delivery of interleukin-2 (AdIL-2) in high-risk localized prostate cancerSuzane Trudel, John Trachtenberg, Ants Toi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 2, 2008
Phase II study of erlotinib in recurrent or metastatic endometrial cancer: NCIC IND-148Amit M Oza, Elizabeth A Eisenhauer, Laurie Elit, et al.
Cancer Treatment and Research Communications|June 1, 2026
CRI-CCTG-0003/IND.240 an immunotherapy platform study in platinum-resistant high grade serous ovarian cancer (IPROC): Sub-studies A and B: Durvalumab (D) + mecbotamab vedotin (BA3011) or ozuriftamab vedotin (BA3021)Helen J MacKay, Anna V Tinker, Brad H Nelson, et al.
Clinical Colorectal Cancer|January 7, 2011
Phase I trial of oxaliplatin, infusional 5-fluorouracil, and leucovorin (FOLFOX4) with erlotinib and bevacizumab in colorectal cancerWells A Messersmith, Antonio Jimeno, Heather Jacene, et al.
Pageof 8

Showing results (31-40 of 71) with videos related to

Sort By:
Pageof 8
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 21, 2007
Randomized trial of high-dose chemotherapy with autologous peripheral-blood stem-cell support compared with standard-dose chemotherapy in women with metastatic breast cancer: NCIC MA.16Michael Crump, Stefan Gluck, Dongsheng Tu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 15, 2010
Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago phase II consortiumSonali M Smith, Koen van Besien, Theodore Karrison, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 19, 2007
Phase I targeted combination trial of sorafenib and erlotinib in patients with advanced solid tumorsIgnacio Duran, Sebastien J Hotté, Holger Hirte, et al.
European Journal of Human Genetics : EJHG|July 18, 2013
Testing personalized medicine: patient and physician expectations of next-generation genomic sequencing in late-stage cancer careFiona A Miller, Robin Z Hayeems, Jessica P Bytautas, et al.
Investigational New Drugs|August 5, 2004
Phase I/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugsSusan M Chang, John Kuhn, Patrick Wen, et al.
International Journal of Radiation Oncology, Biology, Physics|November 3, 2009
Molecular and clinical responses in a pilot study of gefitinib with paclitaxel and radiation in locally advanced head-and-neck cancerCarter Van Waes, Clint T Allen, Deborah Citrin, et al.
Cancer Gene Therapy|September 23, 2003
A phase I trial of adenovector-mediated delivery of interleukin-2 (AdIL-2) in high-risk localized prostate cancerSuzane Trudel, John Trachtenberg, Ants Toi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 2, 2008
Phase II study of erlotinib in recurrent or metastatic endometrial cancer: NCIC IND-148Amit M Oza, Elizabeth A Eisenhauer, Laurie Elit, et al.
Cancer Treatment and Research Communications|June 1, 2026
CRI-CCTG-0003/IND.240 an immunotherapy platform study in platinum-resistant high grade serous ovarian cancer (IPROC): Sub-studies A and B: Durvalumab (D) + mecbotamab vedotin (BA3011) or ozuriftamab vedotin (BA3021)Helen J MacKay, Anna V Tinker, Brad H Nelson, et al.
Clinical Colorectal Cancer|January 7, 2011
Phase I trial of oxaliplatin, infusional 5-fluorouracil, and leucovorin (FOLFOX4) with erlotinib and bevacizumab in colorectal cancerWells A Messersmith, Antonio Jimeno, Heather Jacene, et al.
Pageof 8